N,N-二甲基-3-[10,11-二氢-5H-二苯并(a,b)环庚三烯-5-亚基]-1-丙胺盐酸盐
|
A129730-25g
|
≥98% |
549-18-8 |
25g
|
¥ 416.9
|
现货 |
阿拉丁 |
N,N-二甲基-3-[10,11-二氢-5H-二苯并(a,b)环庚三烯-5-亚基]-1-丙胺盐酸盐
|
A129730-5g
|
≥98% |
549-18-8 |
5g
|
¥ 104.9
|
现货 |
阿拉丁 |
盐酸托莫西汀
|
A129721-1g
|
≥98% |
82248-59-7 |
1g
|
¥ 136.9
|
现货 |
阿拉丁 |
盐酸托莫西汀
|
A129721-250mg
|
≥98% |
82248-59-7 |
250mg
|
¥ 41.9
|
现货 |
阿拉丁 |
盐酸托莫西汀
|
A129721-50mg
|
≥98% |
82248-59-7 |
50mg
|
¥ 29.9
|
现货 |
阿拉丁 |
AMG-517,TRPV1拮抗剂
|
A129715-25mg
|
Moligand™, ≥99% |
659730-32-2 |
25mg
|
¥ 2248.9
|
现货 |
阿拉丁 |
AMG-517,TRPV1拮抗剂
|
A129715-5mg
|
Moligand™, ≥99% |
659730-32-2 |
5mg
|
¥ 538.9
|
现货 |
阿拉丁 |
苹果酸阿莫曲坦
|
A129703-50mg
|
≥98% |
181183-52-8 |
50mg
|
¥ 94.9
|
现货 |
阿拉丁 |
苹果酸阿莫曲坦
|
A129703-10mg
|
≥98% |
181183-52-8 |
10mg
|
¥ 88.9
|
现货 |
阿拉丁 |
盐酸阿那格雷
|
A129685-50mg
|
≥98% |
58579-51-4 |
50mg
|
¥ 254.9
|
现货 |
阿拉丁 |
阿伐那非
|
A129676-250mg
|
Moligand™, ≥99% |
330784-47-9 |
250mg
|
¥ 99.9
|
现货 |
阿拉丁 |
阿伐那非
|
A129676-50mg
|
Moligand™, ≥99% |
330784-47-9 |
50mg
|
¥ 25.9
|
现货 |
阿拉丁 |
阿尔维林柠檬酸盐
|
A129661-25g
|
≥99% |
5560-59-8 |
25g
|
¥ 1151.9
|
现货 |
阿拉丁 |
阿尔维林柠檬酸盐
|
A129661-5g
|
≥99% |
5560-59-8 |
5g
|
¥ 239.9
|
现货 |
阿拉丁 |
苯磺酸阿曲库胺
|
A129655-1g
|
≥98% |
64228-81-5 |
1g
|
¥ 141.9
|
现货 |
阿拉丁 |
苯磺酸阿曲库胺
|
A129655-250mg
|
≥98% |
64228-81-5 |
250mg
|
¥ 59.9
|
现货 |
阿拉丁 |
2-乙酰氨基-5-硝基噻唑
|
A129616-5g
|
≥98% |
140-40-9 |
5g
|
¥ 123.9
|
现货 |
阿拉丁 |
2-乙酰氨基-5-硝基噻唑
|
A129616-1g
|
≥98% |
140-40-9 |
1g
|
¥ 32.9
|
现货 |
阿拉丁 |
AZ 628,适用于BRAF,BRAFV600E和c-Raf的新型Pan-Raf抑制剂
|
A129605-25mg
|
Moligand™, ≥98% |
878739-06-1 |
25mg
|
¥ 1714.9
|
现货 |
阿拉丁 |
AZ 628,适用于BRAF,BRAFV600E和c-Raf的新型Pan-Raf抑制剂
|
A129605-5mg
|
Moligand™, ≥98% |
878739-06-1 |
5mg
|
¥ 587.9
|
现货 |
阿拉丁 |
阿扎佩隆
|
A129598-250mg
|
≥99% |
1649-18-9 |
250mg
|
¥ 342.9
|
现货 |
阿拉丁 |
阿扎佩隆
|
A129598-50mg
|
≥99% |
1649-18-9 |
50mg
|
¥ 92.9
|
现货 |
阿拉丁 |
阿莫沙平
|
A129596-50mg
|
Moligand™, ≥98% |
14028-44-5 |
50mg
|
¥ 144.9
|
现货 |
阿拉丁 |
胺碘酮盐酸盐
|
A129574-25g
|
≥98% |
19774-82-4 |
25g
|
¥ 1015.9
|
现货 |
阿拉丁 |